ArticleBiotechnology letters2025
Enhancing leucine aminopeptidase activity in Aspergillus oryzae LL1 through multi-round UV irradiation mutagenesis with potential application in debittering.
Article in Biotechnology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
To enhance the applicability of Aspergillus oryzae LL1 in the food industry, the strain underwent ultraviolet irradiation through random mutagenesis to enhance the enzyme activity of extracellular leucine aminopeptidase (LAP). A. oryzae LL1 was subjected to three rounds of ultraviolet mutagenesis, and a number of 210, 280, and 290 mutant clones were selected based on LAP activity and stability analysis. The mutant clone with the highest LAP activity was selected for each mutagenesis, and then proceeded to the next round of mutagenesis. The activity of the three selected mutant strains showed significantly increased LAP activity compared to the wild-type strain. The LAP specific activity of A. oryzae LL1 was 319.9 mU/mg. The LAP specific activities of the mutant strains U01, U02, and U03 were 386.3, 449.9, and 556.5 mU/mg, respectively. After three rounds of mutagenesis, the U03 strain exhibited 1.74-fold greater specific activity of LAP than the LL1 strain. A further study evaluated the debittering effect of crude enzyme of the mutant strain U03 on isolated soy protein through hydrolysis and a decrease in the content of hydrophobic amino acids. The mutant strain U03 demonstrated a significantly higher efficiency in hydrolyzing soy protein compared to the LL1 strain, as evidenced by the degradation into small peptide fragments observed in SDS-PAGE analysis, the significant increase in peptide peaks in reverse-phase HPLC analysis, and the higher total free amino acid contents. These results suggest that the U03 strain exhibits more effective hydrolytic activity and holds potential for applications in the food industry, particularly in reducing bitterness in protein hydrolysates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.